Clinical Study
Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer
Table 3
Tumour-infiltrating CD8+ : FOXP3+ T cell ratio in LLABCs(1) and subsequent pathological response to NAC(2).
| |||||||||||||||||||||||||||||||||||||||||
LLABCs: large and locally advanced breast cancers; (2)NAC: neoadjuvant chemotherapy; (3)CD8+ T cell/FOXP3+ Treg ratio; (4)Mann–Whitney test; (5)GPR (good pathological response, grades 5 and 4): no residual invasive disease, >90% loss of invasive disease, respectively; (6)PPR (poor pathological response, grades 3, 2, and 1): 30–90% loss of invasive disease, <30% loss of invasive disease, and no loss of tumour cells, respectively; (7)PCR (pathological complete response, grade 5); statistically significant. |